73 results about "Lymphocytic cell" patented technology

A conjugate contains an amatoxin, a target-binding moiety wherein the target is CD37, i.e., a CD37-binding moiety, and optionally a linker linking the amatoxin and said CD37-binding moiety, and the conjugate is prepared in a synthesis method. A pharmaceutical composition contains the conjugate for use in the treatment of immune cell-, particularly B-cell and / or lymphoma associated diseases and / or malignancies.

The invention provides a construction method and a construction system of a chronic lymphocytic leukemia prediction model based on machine learning, electronic equipment and a storage medium, and relates to the field of chronic lymphocytic leukemia prognosis research. The construction method comprises the steps of obtaining original sample data, and performing preliminary screening; performing data cleaning on the screened sample data; determining a prediction factor from the plurality of features of the cleaned sample data; dividing the cleaned sample data corresponding to the prediction factor and the target variable into a training set and a test set; inputting the training set after unbalance processing into a LightGBM model for training to obtain a prediction model; inputting the test set into a prediction model, performing hyper-parameter optimization on the prediction model, and evaluating the performance of the prediction model; calibrating the prediction model to obtain a calibrated prediction model; the method has the beneficial effects that the method can be realized only by depending on conventionally available predictive factors, and the patient screening can be realized before the CLL clinical symptoms appear.

Provided herein are methods of treating a subject having a CD20 - positive cell-proliferative disorder (e.g., a B-cell proliferative disorder, e.g., non-Hodgkin's lymphoma or chronic lymphocytic leukaemia).SOLUTION: The present invention provides the treatment of a subject having a B-cell proliferative disorder by subcutaneous administration of mosnetuzumab as monotherapy or in combination with lenalidomide.SELECTED DRAWING: Figure 10

This invention relates to the application of PGG in the preparation of drugs for treating acute leukemia, belonging to the field of biomedical technology. To address the problems of narrow application range and easy development of drug resistance in existing acute leukemia treatments, this invention provides the application of PGG in the preparation of drugs for treating acute leukemia. Experiments have shown that PGG can inhibit the viability, proliferation, and colony formation of human acute myeloid leukemia cells (MOLM-13) and human acute lymphoblastic leukemia cells (Jurkat), and induce their apoptosis. In animal models, intraperitoneal injection of PGG can prolong the survival days of mice with acute leukemia and reduce the infiltration of leukemia cells in the liver, spleen, and bone marrow tissues. In this invention, PGG directly inhibits the viability of acute leukemia cells and can simultaneously inhibit AML and ALL, without relying on specific gene mutations, resulting in a lower risk of drug resistance, more flexible clinical use, and broader patient coverage, showing promising clinical application prospects.

Epigenetically modified DNA targeting systems, such as CRISPR-Cas / guide RNA (gRNA) systems, are provided that bind to or target one or more target sites in the IL-2 gene or its regulatory elements in cells such as lymphoid cells (e.g., T cells). In some embodiments, the provided epigenetically modified DNA targeting systems modulate the phenotype or activity of lymphoid cells, or the function of lymphoid cells such as the phenotype or activity of T cells. In some embodiments, methods and uses relating to the provided compositions in the modulation of lymphoid cells such as T cells are also provided, for example, in connection with adoptive T cell therapy.

The present disclosure provides methods of treating a human subject suffering from lung cancer (e.g., non-small cell lung cancer (NSCLC)) using a programmed death-1 (PD-1) pathway inhibitor (e.g., an anti-PD-1 antibody) and synchronous chemoradiotherapy (CCRT, e.g., platinum-based dual drug chemotherapy (PDCT) and radiotherapy), a combination of a PD-1 pathway inhibitor (e.g., an anti-PD-1 antibody) and a lymphocyte activation gene-3 (LAG-3) antagonist (e.g., an anti-LAG-3 antibody) is then used. In some aspects, the methods include a recovery phase that begins after completion of treatment with a PD-1 pathway inhibitor and CCRT, and ends at the beginning of treatment with a combination of a PD-1 pathway inhibitor and a LAG-3 antagonist.

Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. In another embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, carboxymethylcellulose sodium, hydroxypropylmethylcellulose, citric acid monohydrate, disodium hydrogen phosphate, sucralose, sodium methyl parahydroxybenzoate, sodium ethyl parahydroxybenzoate, concentrated hydrochloric acid, sodium hydroxide, and water.

Provided are methods for treating a subject of a solid tumor expressing GPC3 comprising administering to the subject an anti-GPC3 chimeric antigen receptor immunoresponsive cell wherein the administering is performed after or concurrently with subjecting the subject to a lymphopenia treatment. A kit for use in the method is also provided.

The invention relates to the technical field of dendritic cell in-vitro induction methods, and provides a dendritic cell body and an in-vitro induction method and application thereof. Thymic stromal lymphopoietin; the invention relates to a recombinant human FLT3L-Fc fusion protein. And maturing stimulation combination. On the premise of avoiding complex use of equipment, the bottlenecks of DC yield, subgroup purity and functionality are broken through.

The present disclosure relates to CD19 / 22 CAR T-cell products and methods for treating high risk or relapsed CD19+ or CD22+ haematological malignancies.

The present invention relates to the field of cell therapy, and specifically relates to a method for preparing a CAR-expressing T cell and a use. Disclosed in the present invention is a method for preparing a CAR-T cell, comprising the following steps: S1, collecting a T cell-containing cell population of an autologous or allogeneic donor of a subject; S2, administering lymphodepletion therapy to the subject for pretreatment; and S3, administering the T cell-containing cell population and a viral vector to the subject.

The present invention provides the use of isogaminol compounds in combination with glucocorticoids in the preparation of a leukemia treatment drug, belonging to the technical fields of biology and medicine. The isogaminol compounds described herein, when used in combination with glucocorticoids, can enhance the sensitivity of Jurkat cells to glucocorticoids, induce G1 cell cycle arrest in Jurkat cells, and induce apoptosis in Jurkat cells. The combined use of isogaminol compounds and glucocorticoids in the present invention provides a research foundation for overcoming glucocorticoid resistance in acute lymphoblastic leukemia.

The invention belongs to the technical field of virus infection cell lines, and particularly relates to a rats kidney cell line and application thereof. Wherein the preservation number of the kidney cell line of the rats with the yellow chest is CCTCC (China Center For Type Culture Collection) NO: C2025271. The rats kidney cell line (RtK-15W) provided by the invention has multiple advantages of high sensitivity, high replication efficiency, quantitative detection, passage stability and the like on arenavirus; a reliable cell tool and an efficient, reliable and generalizable experimental platform are provided for separation and identification, in-vitro amplification, titer determination, pathogenesis research, drug screening, antibody neutralization experiment, vaccine effect evaluation and the like of arenaviruses (including lymphocytic choriomeningitis virus (LCMV) and Wenzhou virus (WENV)).

The invention belongs to the technical field of blood disease diagnosis, and provides a noninvasive screening method for acute B lymphocytic leukemia (B-ALL) based on a peripheral blood CD3 + CD19 + double positive cell subset, which comprises the following steps: detecting the proportion of CD3 + CD19 + double positive cells in peripheral blood through flow cytometry, and comparing the proportion with a proportion threshold in a positive judgment standard for judgment; when the detection result is greater than or equal to 0.20%, judging that the sample is positive; cD3 + CD19 + double positive cells exist in B-ALL peripheral blood, the detection rate of B-ALL peripheral blood in peripheral blood of healthy people and other types of leukemia patients is extremely low, and the B-ALL has high specificity; compared with bone marrow puncture and other invasive diagnosis methods, the non-invasive primary screening of B-ALL is realized, and the problem of insufficient specificity of the existing non-invasive detection technology is overcome; the kit is suitable for early screening of children B-ALL, dynamic monitoring of chemotherapy curative effect and prognosis evaluation, and has important clinical application value.

Provided is a pharmaceutical combination comprising an antibody specific for CD19 and a natural killer cell, and a treatment method using the same. Such a pharmaceutical combination is capable of exhibiting synergistic therapeutic effects on a malignant tumor of B-cell origin such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and / or acute lymphoblastic leukemia.

The present invention relates to a first composition comprising one of CD4+ T cells and CD8+ T cells for use with a second composition comprising the other of CD4+ T cells and CD8+ T cells in a method for treating a subject having chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), wherein the method comprises administering to the subject a dose of modified T cells comprising CD4+ and CD8+ T cells comprising a chimeric antigen receptor (CAR) that binds specifically to CD19, wherein: (i) the subject has relapsed following remission after treatment with, has become refractory to or has failed treatment with and / or has been intolerant to ibrutinib and venetoclax;(ii) administration comprises administering a plurality of separate compositions, wherein the plurality of separate compositions comprises the first composition comprising one of the CD4+ T cells and CD8+ T cells and the second composition comprising the other of the CD4+ T cells and CD8+ T cells, and (iii) the modified T cell dose comprises a defined ratio of CAR-expressing CD4+ cells to CAR-expressing CD8+ cells, optionally wherein the ratio is between approximately 1:3 and approximately 3:1;

The invention provides application of chidamide or a derivative thereof in preparation of a medicine for preventing and / or treating acute T lymphocytic leukemia. According to statistics of curative effect data of grouped clinical patients, compared with an existing treatment scheme (the curative effect is 20-30%) for treating acute T-ALL, the pharmaceutical composition provided by the invention has the advantages that the curative effect can be improved to 75%, and remarkable clinical benefits are brought.

The invention discloses application of prostaglandin PGE1 or PGE2 in preparation of a product for promoting proliferation of depleted precursor T cells. Specifically, prostaglandin PGE1 or PGE2 is added into a culture system of the T cells for culture, so that the efficiently amplified depleted precursor T cells can be obtained, meanwhile, the depletion degree of the CD8 + T cells can be inhibited, and when the prostaglandin PGE1 or PGE2 is stopped, the depleted precursor T cells can be rapidly and directionally differentiated into the CD8 + T cells. Therefore, when the prostaglandin PGE1 or PGE2 is applied to the in-vitro preparation process of adoptive T cell therapy, the total amount of CD8 + T cells can be remarkably increased, the proportion of Tpex is increased, the expression of a depletion marker is reduced, and a technical support is provided for clinical popularization of solid tumor infiltration lymphocyte therapy.

The invention provides application of a compound inhibitor targeting a G protein coupled receptor ADGRE1, the compound inhibitor is called ADGRE1-i for short, and the molecular formula of the compound inhibitor is C27H22ClN3O3. According to the application, ADGRE1-i is applied to preparation of drugs for treating diseases caused by high expression of ADGRE1, the diseases caused by high expression of ADGRE1 comprise leukemia, and the leukemia comprises acute leukemia, chronic leukemia, hair cell leukemia and juvenile lymphocytic leukemia. The ADGRE1-i inhibits the activation of the ADGRE1 protein and the activation of downstream signal protein through the combination of the targeting interference ligand and the ADGRE1 protein, inhibits the proliferation of leukemia cells, and significantly inhibits the proliferation of AML cells.

This invention discloses a method for obtaining high-purity NK cells using apheresis, belonging to the field of cell culture. The method includes the following steps: (1) obtaining peripheral blood mononuclear cells using the apheresis blood component method; (2) adding NK cell sorting reagent to the peripheral blood mononuclear cells, mixing evenly, and allowing to stand at room temperature to obtain a cell mixture; then adding the cell mixture to the upper layer of lymphocyte separation medium, centrifuging, removing the white membrane layer and above the transparent plasma, washing the harvested cell fluid to obtain enriched NK cells; (3) purifying using CD56 positively selected magnetic beads to obtain purified NK cells; (4) inoculating the purified NK cells into a culture container coated with CD16 antibody and allowing to stand. This method can obtain NK cells with a purity of over 99%, and the cells can expand hundreds of times after 17 days of in vitro culture, exhibiting strong anti-tumor function at low target ratios.

A preparation method of a particle hydrogel includes: mixing a gelatin nanoparticle, a calcium carbonate nanoparticle, an iron oxide nanoparticle, and a sodium alginate solution under alkaline conditions, and adding GDL to produce the particle hydrogel with improved mechanical properties, which is abbreviated as Ca-Alg / MCG. The present disclosure endows the hydrogel system with properties such as catheter injectability, vascular deliverability, and intravascular hardenability. The particle hydrogel can be delivered to fine blood vessels of tumors. The mechanical properties of the particle hydrogel can be gradually enhanced over time, which further improves the embolization efficacy of the particle hydrogel in blood vessels. Magnetic nanoparticles endow the particle hydrogel with magnetothermal responsiveness. Thus, the particle hydrogel can undergo a rapid temperature rise under an alternating magnetic field to further kill tumor cells. The particle hydrogel demonstrates improved embolization efficacy in rabbit renal embolization models and rabbit liver cancer-embolization models.

Provided are DNA-targeting systems, such as CRISPR-Cas / guide RNA (gRNA) systems, that bind to or target a target site in a DLL4 gene or a VCAM1 gene. In some embodiments, the provided DNA-targeting systems promote transcriptional activation of such genes to promote differentiation of hematopoietic progenitor cells into a differentiated population of cells, such as lymphoid progenitor or lymphoid cells. Also provided herein are methods and uses related to the provided compositions, for example in facilitating lymphoid progenitor cell differentiation.

The invention discloses a co-culture method for extracting NK from placenta blood and stimulating by using NK92 cells, which comprises the following steps: 1, separating mononuclear cells: separating the placenta blood by using a lymphocyte separating medium through a density gradient centrifugation method to obtain the mononuclear cells; 2, carrying out induced amplification on the NK cells; according to the method, placenta blood NK cells subjected to primary culture and irradiated NK92 cells are inoculated into a culture medium to start co-culture, in addition, the NK92 cells are subjected to gene editing, genes related to tumorigenicity are knocked out, the tumorigenicity eliminating effect of the NK92 cells is improved, in addition, in a placenta blood NK cell and NK92 cell co-culture system, the placenta blood NK cells and the NK92 cells are co-cultured, and the placenta blood NK cells and the NK92 cells are co-cultured. The cell proportion, culture medium components, culture temperature and humidity are controlled, a standardized co-culture process is established, the influence on the growth, proliferation and functions of the cells is avoided, and the stability of a placenta blood NK cell and NK92 cell co-culture system is ensured.

According to an aspect of the present disclosure, an in vitro method of determining a genotype relating to canine atopic dermatitis (CAD) in a canine mammal may be provided. The method may comprise determining a presence or absence of a splice variant in a signaling lymphocytic activation molecule 1 (SLAMF1) gene of the canine mammal. The presence of the splice variant may indicate that the canine mammal is at increased risk of suffering from CAD and of passing the splice variant to its progeny.

The present invention relates to the development of therapeutic compounds for the treatment of inflammatory bowel disease. In particular, the present invention provides an NLRP3 inhibitor or a pharmaceutically acceptable salt or a suitable composition thereof useful in the treatment of inflammatory bowel disease. These severe and lasting diseases include Crohn's disease and ulcerative colitis, lymphocytic colitis, microscopical colitis, collagenous colitis, autoimmune bowel disease, allergic gastrointestinal disease, eosinophilic gastrointestinal disease, and other related forms of conditions.

The invention discloses a drug combination composition for resisting acute T lymphocytic leukemia and application, the drug combination composition for resisting acute T lymphocytic leukemia comprises an MCL1 inhibitor and afatinib, and the MCL1 inhibitor is S63845. The anti-acute T lymphocytic leukemia drug combination composition is applied to anti-tumor treatment. According to the present invention, the MCL1 inhibitor and the afatinib are combined, such that the significant apoptosis and pyroptosis can be induced, the MYC expression can be significantly reduced, and the purposes of T-ALL tumor cell killing and T-ALL treatment can be achieved.

This invention discloses the application of Huanglian Shangqing tablets combined with glucocorticoids in the preparation of drugs for treating leukemia. The Huanglian Shangqing tablets combined with glucocorticoids can inhibit the activity of Jurkat cells in a concentration-dependent manner; inhibit the proliferation of Jurkat cells in a concentration- and time-dependent manner; and significantly induce apoptosis in the human acute lymphoblastic leukemia cell line Jurkat. In animal experiments, compared with the model group, the Huanglian Shangqing tablets combined with glucocorticoids can increase the hematocrit ratio of leukemia mice, reduce the spleen burden in mice, have no obvious toxic side effects, and improve the survival rate of leukemia mice. Therefore, the Huanglian Shangqing tablets combined with glucocorticoids have the potential value of developing drugs to reverse glucocorticoid resistance in leukemia. Furthermore, Huanglian Shangqing tablets are already used clinically, which can effectively shorten the preclinical research period and has a very good application prospect.

The application discloses application of an SRSF3 inhibitor in preparation of a product for treating and / or preventing acute lymphoblastic leukemia (ALL). The application is based on a protein structure of SRSF3, a molecular docking model of a drug and SRSF3 is simulated by using an artificial intelligence algorithm, drug molecules most likely to be combined with SRSF3 are screened from more than 2,000 drugs approved by the FDA, and the screened drugs are functionally verified through a cell experiment, and finally, the SRSF3 inhibitor capable of being used for treating and / or preventing ALL is obtained.

The application provides a use of vincristine and lithium carbonate as co-active ingredients in the preparation of a medicament for treating tumors. The vincristine and lithium carbonate as co-active ingredients of the application have a killing effect on various leukemia cells, including human acute lymphoblastic leukemia cell lines, chronic myeloid leukemia cells, acute monocytic leukemia cell lines; in particular, for human acute lymphoblastic leukemia cell lines, compared with single free drugs (lithium carbonate or vincristine), lithium carbonate and vincristine free drug combination, the leukemia cell proliferation can be more effectively inhibited; in addition, the vincristine and lithium carbonate as co-active ingredients of the application can obviously stimulate the generation of granulocyte colony-stimulating factor, and alleviate the neutropenia side effect caused by chemotherapy.

Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a thymic stromal lymphopoietin (TSLP) gene. The TSLP RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an TSLP gene. Pharmaceutical compositions that include one or more TSLP RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described TSLP RNAi agents to pulmonary cells, in vivo, provides for inhibition of TSLP gene expression, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including pulmonary inflammation diseases such as asthma, including allergic asthma.